PharmaResearch Unveils Strategic Partnership for Rejuran's European Distribution in 22 Nations

PharmaResearch and VIVACY: A New Era for Rejuran in Europe

PharmaResearch, a prominent name in regenerative medicine, has taken a significant step towards establishing its presence in the European market. The company has officially announced a strategic partnership with VIVACY, a well-recognized player in the medical aesthetics sector based in France. This collaboration aims to distribute Rejuran, PharmaResearch's renowned medical device, across 22 European nations, including pivotal markets such as the United Kingdom, Germany, and France.

The Strategic Significance

This partnership is not just a business move; it represents the fusion of two industry powerhouses joining forces to bring innovative solutions in skin regeneration to Europe. The distribution agreement, valued at approximately €54.5 million over the next five years, highlights PharmaResearch's commitment to growing its brand visibility and market penetration in Europe amid a competitive landscape.

VIVACY's extensive and well-established commercial and marketing network, which extends across key European cities, will serve as a launchpad for the Rejuran brand. With VIVACY's expertise in regulatory compliance and market trends, PharmaResearch is set to accelerate its entry into this lucrative market.

An Unmatched Offering

Jihoon Sohn, the CEO of PharmaResearch, expressed optimism about this collaboration, noting, “Rejuran is currently the only Polynucleotide (PN)-based medical device that has received approval under the EU Medical Device Regulation. Our partnership with VIVACY is expected to bolster Rejuran's global visibility and enhance its status in the international medical aesthetics market.” This sentiment echoes throughout the partnership's framework, emphasizing the unique value proposition that Rejuran offers to healthcare professionals and patients alike.

Bertrand, the CEO of VIVACY, added that the combination of Rejuran's premium positioning, exceptional product quality, and proven efficacy aligns perfectly with VIVACY's strong scientific reputation and commercial capabilities. He stated, “Our collaboration allows us to provide physicians with world-class Polynucleotide technology, reinforcing our commitment to delivering advanced solutions for skin regeneration.”

Market Entry Plans

PharmaResearch's expansion strategy involves rolling out distribution in key European countries within 2025, with plans for a phased approach across the continent. This strategic entry will enable the company to build relationships with leading healthcare providers and enhance the accessibility of Rejuran to a broader patient demographic. Patients and physicians can anticipate the arrival of this innovative skin booster as it leverages cutting-edge technology and research-backed formulations.

About PharmaResearch

Founded in South Korea, PharmaResearch has dedicated itself to enhancing life quality through regenerative medicine innovations. Its portfolio encompasses a variety of products including pharmaceuticals, medical devices, cosmetics, and dietary supplements. The company is known for its proprietary core ingredients, DOT™ PDRN and DOT™ PN, both protected by multiple patents. The recent partnership is expected to significantly contribute to PharmaResearch's growth trajectory, particularly in the European market.

About VIVACY

Laboratoires VIVACY was established in 2007 and specializes in developing premium hyaluronic acid-based medical devices. Its innovative IPN-Like Technology has garnered acclaim for products like STYLAGE® dermal fillers and DESIRIAL®, the first injectable for functional and aesthetic gynecology. VIVACY's commitment to quality and advanced technology is evidenced by its operations across over 85 countries, offering unique solutions for aesthetic applications.

In conclusion, the collaboration between PharmaResearch and VIVACY signifies a major step forward in the evolution of the aesthetics landscape in Europe. As the demand for effective skin treatments grows, the strategic distribution of Rejuran is poised to make a significant impact, ensuring that healthcare providers and patients alike can access this pioneering technology.